SCHEMBL25474397

SCHEMBL25474397

CNCc1cn(CCCN(C)C)c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM2 P50570 4/20 0.68
HTR6 P50406 7/20 0.59
PRKCA P17252 6/20 0.49
PRKACA P17612 3/20 0.49
PRKACG P22612 3/20 0.49
PRKACB P22694 3/20 0.49
PIM1 P11309 2/20 0.49
PRKCB P05771 5/20 0.47
PRKCE Q02156 4/20 0.47
PRKCH P24723 3/20 0.46
PRKCQ Q04759 3/20 0.46
PRKCD Q05655 3/20 0.46
MEN1 O00255 1/20 0.45
PRKD3 O94806 1/20 0.45
CCNB2 O95067 1/20 0.45
CCNE2 O96020 1/20 0.45
TP53 P04637 1/20 0.45
PRKCG P05129 1/20 0.45
CYP1A2 P05177 1/20 0.45
CDK1 P06493 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13908036 0.86 DNM2 (0.76) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL13908035 0.83 DNM2 (0.60) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL25474234 0.81 DNM2 (1.00) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL1093927 0.80 CNR2 (0.48) DNM2HTR6MEN1TSHRKMT2A
SCHEMBL14204507 0.77 DNM2 (0.55) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL8086295 0.77 ICMT (0.71) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL1092646 0.77 CYP19A1 (0.51) DNM2HTR6MEN1TP53KMT2A
SCHEMBL13806549 0.77 PRKCA (0.53) DNM2HTR6PRKCAPRKACAPRKACG
SCHEMBL20307301 0.76 HTR6 (0.81) HTR6
SCHEMBL31544897 0.76 HTR6 (0.71) DNM2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142547-A1 COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION ABIVAX (FR) 2023-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230142547-A1 COMPOUNDS FOR TREATING OR PREVENTING A CORONAVIRIDAE INFECTION & METHODS AND USES FOR ASSESSING THE OCCURRENCE OF A CORONAVIRIDAE INFECTION ACE, ACE2, SARS1 DNM2 1392/4885HTR6 2922/4885PRKCA 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.